Log in
NYSE:PEN

Penumbra Stock Forecast, Price & News

$226.59
+2.47 (+1.10 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$219.30
Now: $226.59
$228.40
50-Day Range
$205.80
MA: $240.10
$272.83
52-Week Range
$121.80
Now: $226.59
$277.00
Volume386,013 shs
Average Volume335,806 shs
Market Capitalization$8.23 billion
P/E Ratio781.37
Dividend YieldN/A
Beta0.67
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; rehabilitation tools that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More
Penumbra logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200
Employees2,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.33 per share
Book Value$13.91 per share

Profitability

Net Income$48.46 million

Miscellaneous

Market Cap$8.23 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$226.59
+2.47 (+1.10 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock price been impacted by Coronavirus?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PEN shares have increased by 28.1% and is now trading at $226.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Penumbra?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Penumbra
.

What stocks does MarketBeat like better than Penumbra?

Wall Street analysts have given Penumbra a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Penumbra wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Penumbra
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) posted its quarterly earnings data on Wednesday, October, 28th. The company reported $0.06 EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.19. The business earned $151.08 million during the quarter, compared to analysts' expectations of $125.60 million. Penumbra had a net margin of 2.02% and a return on equity of 1.25%.
View Penumbra's earnings history
.

What price target have analysts set for PEN?

7 equities research analysts have issued 1 year price targets for Penumbra's shares. Their forecasts range from $192.00 to $292.00. On average, they expect Penumbra's share price to reach $248.86 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts' price targets for Penumbra
.

Are investors shorting Penumbra?

Penumbra saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 4,750,000 shares, an increase of 25.0% from the September 30th total of 3,800,000 shares. Based on an average daily trading volume, of 363,600 shares, the days-to-cover ratio is currently 13.1 days. Currently, 14.1% of the shares of the company are sold short.
View Penumbra's Short Interest
.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), The Boeing (BA) and DexCom (DXCM).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co-Founder, Chairman, Pres & CEO (Age 58, Pay $726.69k)
  • Ms. Maggie S. Yuen, Chief Financial Officer (Age 48, Pay $643.64k)
  • Ms. Johanna Roberts, Exec. VP, Gen. Counsel & Sec. (Age 48, Pay $530.92k)
  • Mr. James Robert Pray, Pres of International (Age 56, Pay $504.29k)
  • Ms. Lynn Rothman, Exec. VP & Chief Bus. Officer (Age 59, Pay $605.13k)
  • Dr. Arani Bose, Co-Founder, Chief Innovator & Director (Age 58)
  • Mr. Ryan Powers, VP of Operations
  • Mr. Lambert Shiu, Chief Accounting Officer (Age 40)
  • Mr. David Barry, Chief Technology Officer
  • Mr. Corey L. Teigen M.D., Chief Scientific Officer

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.27%), William Blair Investment Management LLC (3.38%), State Street Corp (2.21%), Champlain Investment Partners LLC (1.10%), Morgan Stanley (0.92%) and PFM Health Sciences LP (0.66%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra
.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Charles Schwab Investment Management Inc., William Blair Investment Management LLC, State Street Corp, KAMES CAPITAL plc, AXA S.A., Carret Asset Management LLC, and The Manufacturers Life Insurance Company. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder.
View insider buying and selling activity for Penumbra
.

Which major investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, PFM Health Sciences LP, Great West Life Assurance Co. Can, Victory Capital Management Inc., Wetherby Asset Management Inc., JPMorgan Chase & Co., Cubist Systematic Strategies LLC, and BlackRock Inc..
View insider buying and selling activity for Penumbra
.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $226.59.

How big of a company is Penumbra?

Penumbra has a market capitalization of $8.23 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.